Topic: Advancements in Myasthenia Gravis Research: New Horizons in Treatment
A Special Issue of Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Submission deadline: 31 Dec 2024
Guest Editor(s)
Special Issue Introduction
Myasthenia gravis (MG) is a group of autoimmune diseases characterized by fluctuating skeletal muscle weakness, caused by the production of specific antibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) in the body, leading to membrane transmission disorders at the neuromuscular junction.
While MG can occur at any age, it is more common in children and young people, where the disease tends to be more variable. Symptoms often include facial muscle paralysis, particularly affecting the extraocular muscles, as well as fluctuating muscle weakness in the limbs and neck. Early treatment typically involves acetylcholinesterase inhibitors for symptom management, but subsequent immunotherapy is necessary. In traditional treatment, long-term steroid hormone and immunosuppressive therapy have successfully provided long-lasting relief for most patients.
In the past 3-5 years, advances in immune research have led to the development of immune-targeted inhibitors, which are now being explored as potential therapies for autoimmune diseases, including MG. However, these emerging treatments have not yet been widely adopted in clinical practice, and their long-term efficacy and safety remain uncertain, requiring further investigation. It is also unclear whether traditional immunosuppressants will continue to play a role in MG treatment.
This Special Issue aims to provide a comprehensive overview of the current knowledge on MG, with a focus on significant advancements in diagnosis, treatment, and management. We invite submissions of Original Articles, Reviews, Meta-Analyses, Systematic Reviews, Technical Notes, Commentaries, Editorials, Letters to the Editor, and Opinions that explore various aspects of MG, including but not limited to:
● Advances in Diagnostic Techniques: Innovations in genetic polymorphisms, biomarkers, and imaging modalities that improve the accuracy and speed of MG diagnosis;
● Therapeutic Developments: The latest findings in MG therapy and novel treatment strategies;
● Clinical Management and Multidisciplinary Care: Best practices and case studies on managing the diverse and complex symptoms of MG through holistic, patient-centered approaches;
● Pathophysiology and Disease Mechanisms: Insights into the underlying mechanisms of MG and its effects on cellular and organ function;
Patient Quality of Life and Support Systems: Research on improving the quality of life for MG patients, including psychosocial support, patient education, and advocacy.<
We hope this Special Issue will serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of MG patients. By disseminating cutting-edge research and expert insights, we aim to foster a deeper understanding of MG and drive forward the development of effective therapies and comprehensive care strategies.
While MG can occur at any age, it is more common in children and young people, where the disease tends to be more variable. Symptoms often include facial muscle paralysis, particularly affecting the extraocular muscles, as well as fluctuating muscle weakness in the limbs and neck. Early treatment typically involves acetylcholinesterase inhibitors for symptom management, but subsequent immunotherapy is necessary. In traditional treatment, long-term steroid hormone and immunosuppressive therapy have successfully provided long-lasting relief for most patients.
In the past 3-5 years, advances in immune research have led to the development of immune-targeted inhibitors, which are now being explored as potential therapies for autoimmune diseases, including MG. However, these emerging treatments have not yet been widely adopted in clinical practice, and their long-term efficacy and safety remain uncertain, requiring further investigation. It is also unclear whether traditional immunosuppressants will continue to play a role in MG treatment.
This Special Issue aims to provide a comprehensive overview of the current knowledge on MG, with a focus on significant advancements in diagnosis, treatment, and management. We invite submissions of Original Articles, Reviews, Meta-Analyses, Systematic Reviews, Technical Notes, Commentaries, Editorials, Letters to the Editor, and Opinions that explore various aspects of MG, including but not limited to:
● Advances in Diagnostic Techniques: Innovations in genetic polymorphisms, biomarkers, and imaging modalities that improve the accuracy and speed of MG diagnosis;
● Therapeutic Developments: The latest findings in MG therapy and novel treatment strategies;
● Clinical Management and Multidisciplinary Care: Best practices and case studies on managing the diverse and complex symptoms of MG through holistic, patient-centered approaches;
● Pathophysiology and Disease Mechanisms: Insights into the underlying mechanisms of MG and its effects on cellular and organ function;
Patient Quality of Life and Support Systems: Research on improving the quality of life for MG patients, including psychosocial support, patient education, and advocacy.<
We hope this Special Issue will serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of MG patients. By disseminating cutting-edge research and expert insights, we aim to foster a deeper understanding of MG and drive forward the development of effective therapies and comprehensive care strategies.
Submission Deadline
31 Dec 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/rdodj/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=rdodj&IssueId=rdodj240914
Submission Deadline: 31 Dec 2024
Contacts: Cyndi Guan, Assistant Editor, assistant_editor@rdodjournal.com
